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Abstract
Biomarker analysis has been implemented in sports research in an attempt to monitor the effects of exertion and fatigue in
athletes. This study proposed that while such biomarkers may be useful for monitoring injury risk in workers, proteomic
approaches might also be utilised to identify novel exertion or injury markers. We found that urinary urea and cortisol levels
were significantly elevated in mining workers following a 12 hour overnight shift. These levels failed to return to baseline
over 24 h in the more active maintenance crew compared to truck drivers (operators) suggesting a lack of recovery
between shifts. Use of a SELDI-TOF MS approach to detect novel exertion or injury markers revealed a spectral feature which
was associated with workers in both work categories who were engaged in higher levels of physical activity. This feature
was identified as the LG3 peptide, a C-terminal fragment of the anti-angiogenic/anti-tumourigenic protein endorepellin.
This finding suggests that urinary LG3 peptide may be a biomarker of physical activity. It is also possible that the activity
mediated release of LG3/endorepellin into the circulation may represent a biological mechanism for the known inverse
association between physical activity and cancer risk/survival.
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Introduction
The most common mechanism of musculoskeletal injury in the
workplace is overexertion and this relationship has been mainly
derived from injury incidence data and knowledge of the tasks
involved [1,2,3]. As work is usually performed over 8 to12 hour
periods (shifts) these types of analyses are limited in identifying the
levels of activity and potential risk of overexertion and injury.
In sport, biomarkers have been used to evaluate factors which
influence performance such as level of activity and fatigue in order
to design training and workload strategies to enhance performance
[4,5,6,7]. Biomarker monitoring attempts to fine tune an athlete’s
training to induce an ‘over-reached’ state, rather than ‘over-
trained’ state [8,9]. An over-trained state is thought to be a stress
response to excessive training loads and inadequate recovery [8]. It
may also be described as staleness, overwork, burnout and chronic
fatigue [10]. The results of biomarker analysis in elite athletes has
therefore provided a model for examining exertion and fatigue in
heavy industrial workers as similarities exist between the two
situations regarding stimulus [11].
The stimuli for overtraining are multifactorial but generally
involve excessive repetition of specific movement patterns which
may be associated with both high and low magnitude forces [12].
When these loads exceed the repair capacity of musculoskeletal
structures, acute or chronic injury and disorder may occur [13].
While muscle damage may be associated with the breakdown of
muscle specific structural proteins and inflammation, connective
tissue damage is associated with the effects of physical load on the
extracellular matrix of musculoskeletal structures [14]. Further-
more, muscle damage after exercise has been confirmed
objectively by myofibrilar disruption and inflammation, and
indirectly as the perception of soreness and prolonged loss of
strength and range of motion, and infiltration of leukocytes [15].
Many of the biomarkers used to monitor the influence of
training and fatigue in athletes, focus on evaluation of stress
responses, inflammation and altered metabolic states [4,5,6,16].
Cortisol and urea are commonly selected as representative
biomarkers of these conditions. Cortisol is often presented as a
‘stress’ hormone and also functions as an anti-inflammatory and
catabolic enhancer in response to exercise [5]. Indeed, cortisol has
been examined as an indicator of increased catabolic metabolism
in construction workers exposed to 12 hr workdays and extended
work weeks [17], and its circadian function has been shown to
alter in response to shift work in nurses [18]. In addition, elevated
blood urea levels are considered a measure of increased muscle
protein breakdown and are generally increased in over-trained or
fatigued athletes [19,20]. While these biomarkers have not been
extensively used to examine the effects of workload in the
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more accurate indicators of exposure to physical exertion in the
work environment. In regard to the later, protein profiling
approaches such as SELDI-TOF MS have been applied to
discover novel biomarkers of diseases, such as cancer [21,22],
cardiovascular [23,24], and kidney disease [25].
Therefore, in this study we sought to investigate the potential
influence of exposure to varying levels of physical activity in a
cohort of mining workers by analysis of urinary cortisol and urea
levels, and utilisation of a SELDI-TOF MS approach to examine
urinary protein for potential biomarkers of physical activity.
Methods
Ethics Statement
This study was approved by Queensland University of
Technology (QUT) Human Research Ethics Committee (HREC)
(HREC # 3787H and amendment 060000 0188). Participants
completed an informed consent form and a questionnaire
concerning general health information, exercise habits, percep-
tions of work activity levels and recent history of musculoskeletal
injury and disorder. Only subjects who reported that they did not
have any diagnosed pre-existing medical condition, and were
deemed fit for work under Australian workplace regulatory
standards were included in the study. Each participant also
provided 3 urine samples.
Preparation and engagement of workers
Ten healthy male mining industry employees were recruited
from an open-cut coal mine site in central Queensland, Australia.
Although many studies have previously used serum for biomarker
analysis, industrial regulatory requirements and the need to use
procedures acceptable to participants, urinary analysis was
adopted. Therefore, clean catch, midstream urine samples were
collected from each worker at 12 hour intervals. Pre-shift samples
were collected at 18:00 hours prior to commencing an overnight
12 hour shift (PRE). Post-shift samples were collected at the end of
the same shift at 06:00 hours (POST). Additional samples were
collected after a 12 hour recovery period, prior to commencement
of the next shift (24 hr). Samples were stored overnight at 4uC and
then transported on ice to the QUT Institute of Health and
Biomedical Innovation, Brisbane where they were stored at
220uC until required for analysis.
Urea and Cortisol assays
All urine samples were thawed at room temperature and a
single aliquot of each sample was sent to Queensland Medical
Laboratories (Murarrie, QLD, Australia) for analysis. Urinary
urea was measured by an automated kinetic assay, while creatinine
levels were analysed by the Jaffe method (to standardise for
dieresis). Both assays were performed using a Roche Cobas Integra
800 analyser (Roche Diagnostics, Basel, Switzerland; analytic
coefficient of variation of ,4% and ,3% respectively). Urinary
cortisol levels were measured by competitive immunoassay using a
Bayer Centaur Immunoassay System (Bayer Diagnostics, Tarry-
town, NY, USA: analytic coefficient of variation of ,4%).
Sample preparation for SELDI-TOF MS analysis
The remaining thawed sample was clarified by centrifugation at
15006 g for 10 minutes, aliquoted and stored at 220uC until
required for ultra-filtration. Single aliquots of each sample were
then thawed and pre-filtered through a 0.2 mm syringe filter
(supplier) prior to ultra-filtration of 4 mL of sample at 40006g for
40 min using Amicon Ultra-4 3000 NMWL centrifugal ultra-
filtration devices (Millipore, Billerica, MA, USA). The urinary
protein (retentate) was washed with 3.5 mL of milli-Q water
(Millipore) and centrifuged as above to desalt the sample prior to
the storage of individual aliquots at 280uC until required for
analysis. A urine sample obtained from an independent male
subject was identically prepared to serve as a quality control (QC).
The protein concentration of each urinary protein sample was
determined in triplicate by bicinchoninic acid (BCA) protein assay
(Pierce, Rockford, IL, USA) as per the manufacturer’s instructions
and adjusted to 0.42 mg/mL in binding buffer (10 mM sodium
acetate (NaAc), pH 4.5). CM10 (weak cation exchange) Pro-
teinChipH arrays (Bio-Rad, Hercules, CA, USA) were then pre-
equilibrated twice with 50-ml of binding buffer using a ProteinChip
Cassette – Compatible BioprocessorH (Cat # C50-30011)
(BioRad) and placed on a plate shaker for 5 min. Triplicate
35 mL sub-samples of urinary protein and a single QC replicate
sample were applied to the surface of the CM10 arrays in a semi-
randomised fashion to ensure that no replicate samples occupied a
second spot on individual arrays. Since CM10 arrays have
previously been found to provide good quality spectra [26,27]
from urine samples and our own (Unpublished) optimisation
studies using urine samples also demonstrated good spectral
reproducibility and peak number, we elected to utilise this array
type for this study. The samples were allowed to bind for 1 hr on a
plate shaker prior to washing each spot for 365-min with binding
buffer, followed by 261 min washes with ddH2O. The arrays were
allowed to air dry prior to, between and following 261 mL
applications of 50% Sinapinic acid (SPA) in 50% ACN:0.5% TFA.
Each array was then analysed on a PCS 4000 personal edition
SELDI-TOF Mass Spectrometer (Bio-Rad).
Data acquisition, inspection and pre-processing
The QC sample served as a quality assurance measure with the
purpose of determining any batch or chip variability downstream
of the data acquisition. Spectra were generated within the range of
0 to 20000 Da, matrix attenuation was set to 500 Da, focus mass
was set to 5000 Da and sampling rate was set at 800 MHz, A
partition of 1 of 4 was employed and each array spot received 2
warming shots at 1600-nJ and 15 data shots at 1500-nJ. A total of
530 shots per spot were acquired for analysis. Data generated from
the warming shots were excluded from the averaged spectra. A
calibration peptide chip was prepared using pure porcine
dynorphin (2147.5 Da), bovine insulin (5733.5 Da) and bovine
ubiquitin (8564.8 Da) (Bio-Rad) according to the manufacturer’s
instructions and run on the same day as the worker samples.
Using ProteinChipH Data Manager Software 3.0.7 (Bio-Rad),
all spectra were normalised by total ion current between 2000 Da
and 20000 Da. The initial spectral analysis incorporated exclusion
based on Normalisation factor (Nf). Any spectra with a Nf greater
than 2.5 standard deviations from the mean were excluded. Next,
an external calibration equation was generated from the calibrant
spectra and applied to each worker spectrum. A smoothing
window of 25 points was used before fitting the baseline and
filtering parameters were set to ‘on’ with an average peak width of
0.2 times the expected peak width. The spectra were collected and
the peaks were clustered using Cluster wizard
TM (Bio-Rad) with
the following parameters unless otherwise stated; S/N=3.0, valley
depth=3.0, centroid fraction=0.1%, second pass option off.
Individual peak clusters were accepted with m/z coefficients of
variation (CV) of 0.5% or less to ensure accurate peak alignment.
Chip to chip variation was assessed by Pearson’s product-
moment correlations of the QC control spectra in open source ‘R’
statistical computing and graphics program, version 2.10.1 (www.
r-project.org). A regression coefficient of less than r=0.84 was set
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described previously [28]. In order to assess peak reproducibility,
the CVs for individual peaks were calculated for each set of
experimental replicates. Peaks with a CV below 20% were
considered as sufficiently reproducible and were accepted for
further analysis.
Gel electrophoresis and protein isolation
For non-reducing SDS-PAGE, 28.5 mg (Silver staining/protein
ID) or 10 mg (WB) of concentrated urinary protein per sample was
prepared in 46 NuPAGEH LDS sample buffer (Invitrogen,
Carlsbad, CA, USA) and loaded into NuPAGEH 4%–12% bis-
tris gradient gels (Invitrogen). The samples were then electropho-
resed in 16NuPAGEH MES SDS running buffer (Invitrogen) at
200 V for 20 min at 4uC. Silver staining was performed using the
SilverSNAPH Stain Kit II (Pierce) as per the manufacturer’s
instructions.
In order to isolate specific protein bands, a portion of an
unstained duplicate gel corresponding to the band of interest was
excised, placed into an eppendorf tube containing SELDI-TOF
MS binding buffer and finely diced with a razor blade. The diced
gel pieces were incubated at RT for 3 days in 50% ACN after
which the supernatant was transferred to a separate tube and the
gel pieces were then incubated in 100% ACN with shaking for a
further two days. The 2 supernatants were combined and the
protein-containing solution was dried under vacuum in a
centrifuge. The protein pellet was resuspended in 50 mM
NH4HCO3, pH 7, and a portion of the mixture was then applied
to a CM10 protein chip array and subjected to SELDI-TOF MS
as described above.
Protein identification
Concentrated urinary protein (W4 and W5) were run in
triplicate on fresh SDS-PAGE gels. The gels were stained with
Coomassie Blue and the ,20 kDa bands of interest were excised
and then subjected to in-gel digestion. Briefly, the gel pieces were
de-stained and proteins within gel pieces were reduced with
10 mM dithiothreitol, alkylated with 55 mM iodoacetamide,
washed with 50 mM ammonium bicarbonate, pH 7.9 and then
digested for 14 hours at 37uC with trypsin (1:20) before being
extracted into a 60% acetonitrile, 0.1% formic acid solution.. The
digested protein was then subjected to reverse phase LC-MS/MS
using an 1100 Series HPLC (Agilent Technologies, Boblingen,
Germany) coupled with a QStar Elite Quadrupole – Time Of
Flight Mass Spectrometer (Applied Biosystems, Foster City, CA,
USA). The resulting peptide mass spectra were analysed using the
MASCOT search algorithm against the Ludwig Non-Redundant
database and subsequently validated using the Trans Proteomic
Pipeline (TPP) and the Peptide Prophet tool [29,30,31].
Western blot analysis
Concentrated urinary proteins samples were transferred to a
NT nitrocellulose membrane (Pall Corporation, Pensacola, FL,
USA) in 25 mM Tris base, 40 mM Glycine, 10% v/v Methanol,
following SDS-PAGE as described above. The membrane was
blocked overnight in 5% w/v skim milk powder (SMP)/TBST
(100 mM Tris, 150 mM NaCl and 0.1% v/v Tween 20) at 4uC,
washed for 665 min in TBST and incubated for 1 hr at RT with a
goat anti-human endorepellin primary antibody (R&D Systems
Minneapolis, MN, USA) (1:10,000) in 5% SMP/TBST. The
transfer was then washed for 665 min and incubated for 1 hr at
RT with HRP-conjugated rabbit anti-goat secondary antibody
(1:10,000) (R&D Systems) prior to a further 665 min washes with
TBST and detection using an ECL Plus western blot detection kit
(GE Healthcare, Little Chalfont, Buckinghamshire, UK) as per the
manufacturer’s instructions.
Statistical Analysis
Data are presented as mean 6 standard error (SE) or standard
deviation (SD) as indicated. Students t-test (worker physical activity
characteristics) or Mann Whitney-U test (cortisol, urea and m/z
16881 data) were performed to test for group differences with
significance accepted at p,0.05. Pearson correlations were used to
determine the strength of association between replicate control
data to assess potential chip to chip variation.
Results
Subject demographics
The participants comprised 10 healthy male mine workers with
4 working in maintenance (crew) and 6 in truck driving (operators)
work categories. All workers performed a 12- hour overnight shift
at an open- cut coal mining operation in central Queensland,
Australia. The average age of participants was 38.5 years with a
range from 26 to 61 years. Years of service in the mining industry
ranged from 2 to 30 years with an average of 6.9 years. The
average height, weight and BMI 6 SD were 173 cm66 cm,
83.70 kg617.75 kg and 27.97 kg/m
264.79 kg/m
2, respectively.
Six of the 10 workers indicated a previous history of musculoskel-
etal injury, with the most recent injury occurring 3- months prior
to the survey.
Workers perceptions of their exposure to physical activity
during work indicated that those in maintenance categories spent
more time standing and walking during the shift than the
operators (p,0.05) (Table 1). Importantly, only one worker, an
operator (W5), reported performing physical exercise outside of
work hours in the 24 hr period prior to the initial collection of
urine. In terms of general physical activity the crew reported that
they spent significantly less time seated and significantly more time
standing and walking during the shift compared to the operators
(p,0.05) (Table 1).
Urinary urea and cortisol assays
It was established that sampling procedures for mining
employees needed to be non-invasive in order to conform to
workplace requirements. Given that workers were already
involved in occupational urine testing, the ideal source of sampling
was considered to be urine. As reported in table 2, average urinary
urea levels increased significantly at both the post-shift (post)
(p,0.01) and 12 hr post-shift (24 hr) (p,0.01) samples compared
to pre-shift samples (pre). Similarly, urinary cortisol levels
significantly increased post-shift when compared to pre-shift levels
(p,0.05) and remained elevated prior to the next shift (p,0.05).
Interestingly, analysis of the urea and cortisol data for each cohort
indicated that although there was no significant difference in the
Table 1. Summary of physical exposure relative to different
postures and activity.
% of shift spent Maintenance crew Operators (Truck drivers)
Seated 16.5%67.8% (n=4) * 85.9%68.0% (n=6)
Standing 67.2%630.1% (n=4) * 9.1%65.9% (n=5)
Walking 56.1%632.1% (n=3) * 8.4%66.6% (n=5)
*=p,0.05.
doi:10.1371/journal.pone.0033714.t001
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trend in the latter towards recovery. This response is similar to that
expected for a circadian rhythm [18], whereas the crew did not
display a trend toward recovery in urea or cortisol levels, possibly,
suggesting exposure to increased physical stress (Fig. 1a & b).
Urinary protein analysis by SELDI-TOF MS
In this study we generated SELDI-TOF MS profiles of mining
worker urinary proteins to detect novel biomarkers of musculo-
skeletal injury, fatigue and/or physical exertion. Cluster analysis of
the spectra was performed to reveal those spectral peaks which
were associated with either the maintenance crew cohort, who
were engaged in more physically active work, or the operator
cohort, who were less physically active during the shift. This
resulted in a cluster of 59 spectral peaks, of which a block of 3
peaks at m/z 16741.63, 16881.59 and 17038.85 were of particular
interest since these appeared to be up-regulated in the more active
group (Fig. 2a). Analysis of the peak intensities of the central
spectral feature at m/z 16881 indicated that the observed
difference between crew and operators was not statistically
significant (Fig. 2b). However, inspection of the raw spectra
revealed that worker 5 (W5), a member of the operator group, had
peak intensities for the central m/z 16881 peak which were more
similar to those of the crew cohort than others in his work
category. Examination of the self reported out of work activities
revealed that only W5 had engaged in a gym workout in the 24 hr
period prior to urine sampling. Taken together these findings
suggested that W5 might have been more correctly associated with
the physically active maintenance workers than the less physically
active operator work category. Based on this rationale we re-
Figure 1. Urinary urea and cortisol levels trend toward recovery in operators but not in maintenance crew. a) Urinary, urea levels were
determined by an automated kinetic assay (analytic coefficient of variation being ,4%). b) Urinary cortisol levels were determined by competitive
immunoassay (analytic coefficient of variation being,4%). Both urea and cortisol measurements were standardised for dieresis against urinary
creatinine levels which were determined by the Jaffe method (analytic coefficient of variation being,3%).
doi:10.1371/journal.pone.0033714.g001
Table 2. Urinary biomarker values for mine site employees.
a
PRE 18:00 POST 06:00 24 hr 18:00
UREA mM/mM Cr 26.5561.76 38.0062.13* 38.0962.16*
CORTISOL nM/mM Cr 19.0061.53 31.6864.16
# 32.2863.88
#
aValues are means6SE.
*Indicates values are significantly greater than PRE value (P,0.01).
#Indicates value significantly greater than PRE value (P,0.05).
doi:10.1371/journal.pone.0033714.t002
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physically active (operators without W5) for subsequent analysis.
We found a significant difference in peak intensity between the
physically active and non-physically active workers pre-shift
(p,0.05), post shift (p,0.01) and 24 hr (p,0.05) time points
(Fig. 2b). Furthermore, inspection of the raw stacked spectra for
Figure 2. The spectral feature at m/z 16,881 is associated with physically active workers. a) Cluster analysis of SELDI-TOF MS data from
urinary protein of mining workers. The 3 values centred around m/z 16881 constitute a major feature differentiating between crew (Red, Pre, Post &
24 hr) andoperators (Blue, Pre, Post & 24 hr). Red squares indicate peak intensities above theaverage andgreen squares indicate peak intensities below
the average intensity for the specified m/z value. Note block of m/z values centred on m/z 16881. b) Closer examination of the spectral feature m/z
16881 revealed that although the mean peak intensity appeared different between crew and operators at each time point the difference was not
significant. Further examination of individual worker spectra indicated that 1 operator (W5) had a relatively high peak intensity at m/z 16881 in all three
of his samples and according to information provided in the health and physical activity questionnaires W5 was the only participant to have engaged in
a gym workout (resistance training) within the 24 hr period prior to sampling. Thus W5 and the crew were re-classified as the physically active (PA)
cohort (n=5) and the remaining operators were reclassified as the non-physically active (Non-PA) cohort (n=5). The peak intensity of m/z 16881 was
significantly higherin the PA workers compared to the Non-PA workers. Data is the mean peak intensity +/2 SEM. Significance is given as * p,0.05 or #
p,0.01 (Mann Whiney - U Test) c) The spectral feature centred around m/z 16881 (shaded box) generally displays a higher intensity in the physically
active workers compared to workers who were less physically active. Spectral profiles for each worker are stacked replicates (n=3 per profile).
doi:10.1371/journal.pone.0033714.g002
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of the feature surrounding m/z 16881 between the cohorts
(Fig. 2c).
Protein isolation and identification
We then determined that it may be possible to detect this broad
tri-phasic peak by silver stain following SDS-PAGE. Therefore, 2
samples were selected from a crew member (W4 Pre & W4 24 hr)
and 2 samples from an operator (W6 Pre & W6 24 hr) based on
maximum (W4) and minimum (W6) observed spectral peak
intensities for m/z 16881 (Fig. 3a). The W5 pre-shift sample was
also included as we hypothesised that the peak of interest would
appear as a more intensely staining band in the W4 and W5
samples compared to the W6 samples (Fig. 3b). Indeed, we found
an intensely staining band corresponding to an approximate
molecular weight of ,20 kDa in the W4 and W5 samples which
did not appear as intense in the W6 samples (Fig. 3b).
In order to confirm that the intensely staining band was indeed
the tri-phasic peak detected in the SELDI spectra at m/z 16881
we again performed the SDS-PAGE with the same samples in
replicate gels. The ,20 kDa band was excised, isolated and
subjected to SELDI-TOF MS. We detected a tri-phasic peak at
the corresponding m/z to the original analysis, although the
intensity was much lower than in the original spectra (Fig. 3c).
This was not unexpected since we only used a portion of the
diffused protein from the excised gel piece. This data indicated
that the protein band observed and excised from the SDS-PAGE
gel was in fact the same protein responsible for the tri-phasic peak
detected in the original SELDI-TOF mass spectra at m/z 16881.
To identify the protein, or proteins, contained in the ,20 kDa
band and the spectral feature surrounding m/z 16881, triplicate
gel pieces from 2 individual workers (W4 and W5) were excised
from freshly prepared gels. The protein contained in the gel pieces
was then subjected to in-gel digestion and the tryptic peptides were
analysed by LC-MS/MS. The resulting peptide mass spectra were
analysed using the MASCOT search algorithm. A specific
fragment of the Basement Membrane Specific Heparin Sulphate
Proteoglycan Core Protein – 2 (HSPG2) or Perlecan, Non-
Secretory Ribonuclease were identified with high probability
scores (all .54) (Table 3). The MS/MS data were then validated
using the Trans Proteomic Pipeline (TPP) and the Peptide Prophet
tool which resulted in a return of 30 spectra with probability scores
above the calculated Minimum Probability Threshold (MPT) of
0.76, corresponding to p=0.05. Twelve of these 30 peptides (with
a MPT of .0.91, p=0.025) corresponded to peptides which
directly identified the Perlecan protein LG3 fragment (Table S1).
Analysis through Protein Prophet gave a confidence value of 1.000
for both the Perlecan protein (fragment) and the Perlecan protein
with the probability for these as 1.0000 and 0.9899, respectively
(Table S2). Further analysis of the Perlecan sequence indicated
that the peptides identified by MS/MS mapped exclusively to
domain 5 of the parent protein and specifically to the C terminal
LG3 peptide. Domain 5 of perlecan is also known as endorepellin
which itself is a bioactive derivative of perlecan once enzymatically
liberated [32,33]. The LG3 peptide molecule spans 195 amino
acids (residues 4197–4391 of the parent protein) and has a
theoretical mass of 20549 Da which corresponds with the protein
band observed on the gel (Fig. 3b). However, the theoretical mass
did not correspond to the original m/z 16881 feature detected in
the original SELDI-TOF MS data. In order to further characterise
the sequence coverage of our MS/MS data and to account for this
apparent discrepancy, we performed an in silico trypsin digest of
the LG3 peptide using the Peptide Mass tool on ExPasy
Proteomics Server. We found that the peptides identified by LC-
MS/MS matched the in silico generated tryptic fragments and
collectively resulted in 95.9% sequence coverage of the putative
LG3 peptide (Fig. 4a and Table S3). Interestingly, our MS/MS
data did not identify any sequence from the first 25 residues of the
LG3 peptide. The sequence coverage of our experimental data
spanned 158 amino acids incorporating residues 26 to 183 of the
Figure 3. The spectral feature at m/z 16881 is a broad tri-phasic peak, visible by SDS-PAGE. a) The hypothesised pattern of intensity of
m/z 16881 in stacked replicate spectra, expected to be observed in an SDS-PAGE gel. b) A band which matched the expected pattern of intensity for
the feature at m/z 16881 was detected at ,20 kDa by SDS-PAGE (arrow) suggesting that the bands at ,20 kDa in the gel were the proteins which
constituted m/z 16881 in the spectra. c) The protein at ,20 kDa was extracted from excised bands from a non-stained replicate SDS-PAGE gel.
Examination of the extracted protein by SELDI-TOF MS confirmed that the ,20 kDa band was the feature originally detected at m/z 16881.
doi:10.1371/journal.pone.0033714.g003
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33714Figure 4. LC- MS/MS identifies the LG3 peptide of endorepellin, a C-terminal bioactive fragment of Perlecan. a) Perlecan (underlined
bold lower case), the C terminal of Perlecan containing Endorepellin (lowercase text) and the LG3 Peptide of endorepellin (BOLD CAPITALS).
Individual peptides identified by LC-MS/MS of tryptic in-gel digest in LIGHT GREY and DARK GREY highlights. Sequence coverage includes the
LG3 peptide, however, the first 25 residues of the LG3 peptide were not detected. b) Western blot analysis confirmed that the ,20 kDa protein
observed by SDS-PAGE and the spectral feature at m/z 16881 are derived from endorepellin. Western Blot of worker urine samples using goat anti-
human endorepellin polyclonal antibody (1:10,000).
doi:10.1371/journal.pone.0033714.g004
Table 3. The ,20 kDa band excised from the SDS-PAGE gel is a fragment of perlecan.
Sample Acc. No. Proteins Mass (kDa) Score
a Matching peptides
W4 Pre P98160 Basement membrane-specific heparan sulfate proteoglycan core protein 479.3 329 10
P10153 Non-secretory ribonuclease 18.8 180 4
W4 Pre P10153 Non-secretory ribonuclease 18.8 140 4
Q59EG0 Basement membrane-specific heparan sulfate proteoglycan core protein (Fragment) 249.9 130 5
W4 Pre P10153 Non-secretory ribonuclease 18.8 102 3
Q59EG0 Basement membrane-specific heparan sulfate proteoglycan core protein (Fragment) 249.9 71 3
P98160 Basement membrane-specific heparan sulfate proteoglycan core protein 479.2 67 3
W5 Pre Q59EG0 Basement membrane-specific heparan sulfate proteoglycan core protein (Fragment) 249.9 211 7
P98160 Basement membrane-specific heparan sulfate proteoglycan core protein 479.2 204 7
P10153 Non-secretory ribonuclease 18.8 123 4
W5 Pre Q59EG0 Basement membrane-specific heparan sulfate proteoglycan core protein (Fragment) 249.9 169 6
P98160 Basement membrane-specific heparan sulfate proteoglycan core protein 479.2 162 6
P10153 Non-secretory ribonuclease 18.8 53 2
W5 Pre P98160 Basement membrane-specific heparan sulfate proteoglycan core protein 479.2 275 9
P10153 Non-secretory ribonuclease 18.8 133 4
Mascot search results.
aIons score is 210*log(P), where P is the probability that the observed match is a random event. Individual ion scores .52 indicate identity of extensive homology
(p,0.05).
doi:10.1371/journal.pone.0033714.t003
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and had a theoretical mass of 16641 Da, which more closely
corresponded to the m/z of our original SELDI-TOF MS
experimental data.
In order to further confirm that the protein band observed at
,20 kDa was indeed derived from perlecan/endorepellin we
subjected 4 worker urine samples which exhibited high (W4 Pre
and W5 Pre) and low (W6 Pre and W10 Pre) intensity SELDI-
TOF MS peaks at m/z 16881 to western blot analysis using a
polyclonal antibody raised against full length endorepellin. A
strong immunoreactive band was observed which corresponded to
the ,20 kDa band observed in the silver-stain of worker urinary
protein, indicating that the band was derived from endorepellin
(Fig. 4b). Moreover, the intensity of the bands was consistent with
the difference in intensity of the peaks at m/z 16881 observed in
the original SELDI-TOF MS data. (Unfortunately, we were
unable to perform additional analysis of the samples from the
current study due to insufficient sample). Additional analysis of
urine samples provided ad libitum from an additional 6 workers
from a separate study revealed variation in LG3 expression over a
shift, suggesting acute expression and thus coordination between
sample collection and the inducing activity may be important (Fig
S1, S2, S3). The strongest and most consistent expression was
detected in single maintenance worker (Fig S2), According to self
report, none of the workers from the separate study had engaged
in intensive physical activity prior to the sampling period. In
addition, the Non Secretory Ribonuclease, which was co-identified
by mass spectrometry, exhibited an increasing but different pattern
of expression across an individual time course series compared to
the LG3 peptide (Fig S4).
Discussion
Despite increased automation of tasks with high risk of injury,
many tasks are unable to be redesigned and this is demonstrated in
task analyses of maintenance workers in mining which are
described as a combination of interspersed intensive resistance
exertion and light to moderate aerobic physical activity [34].
Furthermore, the overall length of exposure to such exertion is a
contributing factor to injury and a factor potentially responsible
for the persistent increase in urinary urea and cortisol levels
observed in the maintenance workers in this study. While there is
prior evidence for increased urea excretion in response to acute
resistance exercise [35], altered levels may also be associated with
activities of higher intensity and longer duration [36,37], or dietary
amino acid catabolism [38]. As such, caution in the interpretation
of physical activity levels based on urea production alone is
imperative. Similarly, caution must be applied in the interpreta-
tion of cortisol responses, since cortisol secretion exhibits a
circadian rhythm where levels peak in the morning and nadir at
night [18]. In our study, cortisol and urea levels were measured in
samples collected before and after the second night shift of the
roster. Thus it is possible that the differences between pre- and
post-shift values were due to normal circadian variation in cortisol
secretion. Indeed, this may explain the observed trend toward
recovery in cortisol levels for the operators in the 24 hr post-shift
sample (Fig. 1). However, there was no observed recovery in
cortisol levels for the maintenance crew, which suggests there is a
difference between the 2 cohorts in terms of stressors.
It has been hypothesised that long hours and extended working
periods may not enable sufficient recovery from work and may
contribute to health problems in workers [39]. While our data may
support this hypothesis, a study by Garde et al. (2006) found no
difference in cortisol levels between employees working extended
hours (12 hour work days and longer rosters) compared to those
with regular (8 hr) work schedules [40]. However, this discrepancy
may be explained by sampling conditions, since the authors
measured cortisol in saliva samples over day shifts, while our urine
samples were collected spanning the second night shift of the
roster. Indeed, while it is possible for some workers to develop a
tolerance to shift work and adapt their cortisol functions
accordingly, evidence suggests that this does not occur until the
fifth night of the roster [18]. Conversely, other studies have
observed lower cortisol values when sampled in the morning
following night work [41,42], rather than increased values as we
observed in the crew cohort. These studies involved health care
workers who may not be subjected to the same level of physical
activity as those in mining activities as in this study. When
considered together, our cortisol and urea data support the
hypothesis that there is a lack of recovery from work in the
maintenance crew compared to the more sedentary operator
cohort.
The analysis of worker urinary protein by SELDI-TOF MS
offered an additional means by which to discover novel biomarkers
of musculoskeletal injury or of exposure to associated risk factors,
such as prolonged physical activity. The initial cluster analysis of
our SELDI-TOF MS data revealed that a number of m/z peaks
were associated with either the maintenance or driver cohorts.
The most striking of these was a tri-phasic cluster with a central
m/z of 16881 (Fig. 2), which we were subsequently able to
visualise by SDS-PAGE (Fig. 3) and identify as containing Non-
Secretory Ribonuclease (NSR) and the LG3 peptide of endor-
epellin using LS-MS/MS (Fig. 4, tables S1, S2, S3 and Fig S4).
While the NSR, otherwise known as Eosinophil Derived
Neurotoxin (EDN) was not examined further in this study we
did compare its expression to that of the LG3 in a separate study
and found it to increase across a time course series in a single
worker (Fig S4). While the significance (if any) of this expression
pattern remains unknown it is possible that it may also be
associated with physical activity level but exhibits a less acute
expression than the LG3 peptide. Urinary expression of the NSR/
EDN has been associated with eosinophil degranulation and
allergic conditions such as atopic dermatitis and asthma [43,44].
The NSR/EDN is also expressed in macrophages and is involved
in inflammatory processes and the innate immune response
inflammatory [45]. Therefore, it may be interesting in longer term
controlled studies to further examine the release profile of the
NSR/EDN following different levels of physical activity intense
physical activity can illicit inflammatory effects.
To the best of our knowledge this is the first study to
demonstrate that physically active workers have higher urinary
levels of the LG3 peptide of endorepellin. The LG3 peptide is the
C-terminal bioactive proteolytic fragment of endorepellin, which is
itself an 80 kDa bioactive C-terminal protein of perlecan [32].
Interestingly, perlecan is a major extracellular matrix constituent
of all basement membranes and significantly, articular cartilage,
and neuromuscular junctions [46,47,48]. In 2003, Mongiat et al.
hypothesised that endorepellin might be released from articular
cartilage during remodelling or inflammation [32]. Given that
during intense physical activity/exercise, both muscle tissue
[49,50,51] and articular cartilage [52] are subjected to forces
capable of inducing inflammation and tissue remodelling process-
es, the appearance of the LG3 peptide of endorepellin in the urine
of physically active mining workers, as described in this study,
supports the hypothesis proposed by Mongiat et al. (2003).
While perlecan is known to have pro-angiogenic functions in
vivo, its C-terminal bioactive fragment, endorepellin, is an inhibitor
of angiogenesis [32]. Furthermore, the LG3 peptide, originally
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been characterised as the anti-angiogenic moiety of endorepellin
[32,54]. More recently, Chang et al. (2008) reported that
conditioned media from the malignant breast cancer cell line,
Hs578T, was found to have lower levels of LG3 peptide compared
to the non-tumour breast cell line Hs578Bst [55]. Moreover, these
authors found that breast cancer patients (n=6) had lower levels of
circulating LG3 peptide compared to healthy volunteers (n=6)
and therefore proposed that low circulating LG3 peptide might be
a potential biomarker of breast cancer [55]. It is important to note
here that our data may provide a different interpretation to the
results reported by Chang et al. (2008), in that it is possible that the
healthy volunteers recruited for their study were simply more
active than the cancer patients prior to sample collection [55].
Moreover, it is unlikely that one will observe lower levels of
circulating LG3 in cancer patients if their tumour is secreting
lower levels than the rest of the body, as suggested by the authors
finding that breast cancer cells produced lower levels of LG3 in
vitro. Chang et al. (2008) also noted that the only other studies
which had described altered LG3 peptide levels were associated
with urine analysis of patients with end stage renal failure [53] and
in amniotic fluid during premature foetal membrane rupture in
pregnant women [56]. Our data provides evidence for a potential
additional explanation for the appearance of the LG3 peptide in
urine. Clearly the exact nature and circumstances surrounding the
alteration to circulating and urinary LG3 peptide or endorepellin
requires further investigation.
In further support of our data, the LG3 peptide is known to be
proteolytically released from endorepellin and perlecan by both
bone morphogenetic protein–1 (BMP-1)/Tolloid like Metallopro-
tease [33] and caspase-3 mediated Cathepsin-L mechanisms [57].
Recent studies have demonstrated that BMP-1 is released from
cartilage explants following exposure to mechanical injury or to
either of the inflammatory cytokines tumour necrosis factor-a
(TNF-a) or interleukin-1b (IL-1b) [58]. Both of these cytokines are
found in rheumatoid and osteoarthritic synovial fluid [59] and
have both been shown to stimulate the expression of cathepsins in
endothelial cells, macrophages and smooth muscle cells [60].
Thus, the mediators of two of the known mechanisms of LG3
peptide liberation are present and active in the articular cartilage/
synovial environment and/or musculoskeletal tissues generally.
Moreover, eccentric exercise is known to induce inflammatory
responses such as leukocyte accumulation and up regulation of
cytokines in exercised muscles [15,61]. When considered together,
these data provide an additional potential source and explanation
for the increase in LG3 peptide in the urine of physically active
mining workers.
The LG3 peptide/endorepellin is among a number of
proteolytic fragments from articular cartilage and basement
membrane proteins which have anti-angiogenic/angiostatic ef-
fects. These include endostatin, tumstatin and arrestin, all C-
terminal peptides derived from collagen XVIII and the a3 and a2
chains of collagen IV respectively. In support of our data, treadmill
running exercise has been shown to transiently increase circulating
levels of endostatin in healthy male subjects relative to individual
levels of oxygen consumption [62], suggesting that endostatin
reflects the level of physical exertion. Thus, it would be very
interesting to ascertain if exposure to intensive physical activity
also induces the release of either tumstatin or arresten peptides.
Our results have shown that the LG3 peptide is elevated in the
urine of physically active workers, and that a number of anti-
angiogenic peptides are known to be released from matrix proteins
present in articular cartilage and/or in response to inflammatory
cues or exercise. As such, we would like to propose our own
‘‘provocative hypothesis’’ in the spirit of that postulated by
Mongiat et al. (2003) [32]. It is possible that the physical activity
induced release of LG3 peptide/endorepellin, and other similar
anti-angiogenic fragments of ECM components, may be one of the
physiological mechanisms for the well documented but still not
clearly understood link between physical activity and reduced
cancer risk or improved survival from cancer [63,64,65]. Indeed,
recombinant human endorepellin administration to the peritoneal
cavity of nude mice or C57BL/6 mice inoculated with A431
human squamous cell carcinoma cells or Lewis lung carcinoma,
respectively, restricted tumour development by specific disruption
of tumour neovasculature. This resulted in tumour hypoxia,
reduced proliferation, metabolism and increased tumour cell
apoptosis. In addition, endostatin, tustatin and arresten have all
been shown to inhibit tumour development in various model
systems [66,67,68,69]. While our proposed hypothesis remains to
be tested, it is also important to address a number of limitations in
our study. Firstly, the association between urinary LG3 peptide
and physically active mining workers was observed in a small
sample population and is therefore quite preliminary in nature and
requires further validation in controlled laboratory settings with
larger cohorts. Secondly, that the level of intensity and duration of
physical activity required for LG3 peptide/endorepellin release
remains to be established. This is most achievable within a
laboratory environment as stated above. These studies are
required in order to fully appreciate if urinary LG3 peptide levels
reflect pathological injury or (as we have speculated in the above
hypothesis) a therapeutic level of activity.
In conclusion, we have for the first time, described a potential
association between urinary LG3 peptide levels and physical
activity in a cohort of mining workers. Thus, we propose that
urinary LG3 peptide may serve as a biomarker of physical activity,
a known risk factor when inappropriately prescribed for
musculoskeletal injury. Such biomarkers could be utilised in
musculoskeletal injury risk assessment and management in the
heavy industrial and sport sectors in order to reduce the risk and
enhance interventions to prevent musculoskeletal injury. More-
over, due to the well established anti-angiogenic/anti-tumorigenic
activity of LG3/endorepellin, we also propose that physical
activity induced release of LG3/endorepellin may be a possible
biological mechanism explaining the relationship between cancer
risk/survival and physical activity.
Supporting Information
Figure S1 Normalised LG3 expression in a time course
of urine samples from Worker 12 (maintenance worker).
a) Dot blot using the same sample as prepared for SDS-PAGE to
allow normalisation for loading. b) Western blot for the LG3
peptide. c) Normalised densitometry data relative to the LG3
expression in an unrelated sample used as a normalisation
standard for each subsequent western blot (as indicated in Fig
S1, S2, S3). Dot Blot (loading control) and Densitometry
of Supplementary Western Blots Method: SDS-PAGE
Samples were taken out of the 280uC and placed on ice.
1.16 mg of total protein was prepared in separate tubes to a total
volume of 28 mL for each sample 1. The content in each tube was
mixed and pulse centrifuged. 2. 4 mL of each sample was
transferred to clean eppendorf tubes for dot blot analysis
(evaluation of loading). 3. 8 mL of loading buffer was added to
the remaining 24 mL of samples. 4. The content in each tube was
mixed and pulse centrifuged. 5. The samples were loaded into a 15
well NuPAGE Tris HCL 4–12% gradient gels. 6. The samples
were electrophoresed in NuPAGE MES buffer at 200 V constant
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transferred to a nitrocellulose membrane using Semi-dry Transfer
for 90 minutes at 45 mAmps/gel Western Blotting Following
protein transfer the nitrocellulose membranes were blocked in 5%
skim milk powder in Tris buffered saline/0.1% Tween 20 (TBST)
for 1 hour at room temperature (RT) on a shaker and protected
from contaminants with aluminium foil. 1. The blocked
membrane was incubated with either a goat anti-human
Endorepellin polyclonal antibody as primary (1:10,000 dilution)
or a rabbit anti-Eosinophil derived neurotoxin polyclonal antibody
as primary (1:2,500 dilution) for 1 hour at RT on a shaker. 2. The
membrane was washed in TBST for 665 minutes at RT on a
shaker. 3. The membrane was incubated in a either a 1:10,000
dilution of rabbit anti-goat IgG HRP-conjugated secondary
antibody or a 1:5000 dilution of donkey anti-rabbit IgG HRP-
conjugated secondary antibody as appropriate in TBST for
30 minutes at RT on a shaker. 4. The secondary antibody was
removed and the membrane was washed in TBST for 665 min-
utes at RT on a shaker. 5. Each membrane and strip was
transferred to a clean white weighing tray and incubated in
Amersham
TM ECL
TM Prime western blot detection reagent (GE
Healthcare Ltd, Little Chalfont, Buckinghamshire, UK) as per
manufacturer’s instructions. 6. Chemiluminescence was captured
by exposure of the membrane to X-Ray film (Fujifilm, Tokyo,
Japan) and subsequently developed using an Agfa automated film
developer CP-1000 (Mortsel, Belgium). Dot Blot 1. 2 mL of each
sample (prepared as above) was transferred to a nitrocellulose
membrane strip and allowed to air dry. 2. To visualise the protein
spots the membrane was reversibly stained using MemCode
TM
Reversible Protein Stain Kit (Peirce, Rockford, IL, USA) as per
manufacturer’s instructions. Briefly, A. Stain 1. The nitrocellulose
membrane containing the proteins was rinsed with milliQ water
and quickly decanted. 2. 1 mL of MemCode
TM Reversible Protein
Stain was added to the nitrocellulose membrane. 3. The
membrane was placed on a shaker at room temperature for
30 seconds (Stained proteins appear as turquoise-blue bands). B.
Destain (remove background) 1. 1 mL of MemCode
TM
Destain Reagent was added to the membrane and removed after a
few seconds. This step was repeated two additional times. 2. 1 mL
of the Destain Reagent was added to the membrane and agitated
for 5 minutes on a shaker. 3. The membrane was rinsed four times
by adding milliQ water to the tray and decanting after a few
seconds. 4. The membrane was washed with milliQ water for
5 minutes on a shaker with agitation. Densitometry 1. A digital
image of the dot blot was obtained using gel doc or of western blot
films using a flatbed scanner. 2. Densitometry was performed
using Image J (NIH).
(TIF)
Figure S2 Normalised LG3 expression in a time course
of urine samples from Workers 13 & 14 (maintenance
workers). a) Dot blot using the same sample as prepared for
SDS-PAGE to allow normalisation for loading. b) Western blot for
the LG3 peptide. c) Normalised densitometry data relative to the
LG3 expression in an unrelated sample used as a normalisation
standard.
(TIF)
Figure S3 Normalised LG3 expression in a time course
of urine samples from Workers 15, 16 & 18 (operators).
a) Dot blot using the same sample as prepared for SDS-PAGE to
allow normalisation for loading. b) Western blot for the LG3
peptide. c) Normalised densitometry data relative to the LG3
expression in an unrelated sample used as a normalisation
standard.
(TIF)
Figure S4 Comparison of Normalised LG3 and Non
Secretory Ribonuclease (NSR) expression in a time
course of urine samples from Worker 13. a) Dot blot using
the same samples as prepared for SDS-PAGE to allow
normalisation for loading. Western blot for b) the LG3 peptide
or c) NSR. Normalised densitometry data for d) LG3 expression or
e) NSR expression. The data in d & e are presented as relative to
an unrelated sample derived from a physically active participant in
a separate study (V15 BL2). Both the LG3 peptide and the NSR
were identified by mass spectrometry of an in gel digest of the
20 kDa band observed and excised from an SDS-PAGE gel . The
data from this sample provides additional data indicating that the
NSR and the LG3 are co-identified in the same 20 KDa band.
Recombinant NSR served as a positive control for NSR
expression.
(TIF)
Table S1 Peptides from all samples validated through
the TPP – these 4 peptide sequences, out of the 10
identified from MS/MS spectral data, were validated
with greater than 95% confidence. The remaining 6 peptides
either had a MASCOT ion score below 57 or were lower than the
95% confidence interval as calculated by PeptideProphet.
(DOC)
Table S2 Analysis through Protein Prophet gave a
confidence value of 1.000 for both the Perlecan protein
(fragment) and the Perlecan protein with the probability
for these as 1.0000 and 0.9899, respectively.
(DOC)
Table S3 In silico trypsin digest was performed on the
LG3 peptide using the PeptideMass tool on the ExPASy
Proteomics Server. The following options were selected:
cysteines treated with iodoacetomide; methionines oxidized with
[M+H]
+; monoisotopic peptides; no allowed missed cleavage; and
peptides larger than 500 Da. The MS/MS data (indicated by the
stars) fits with the data generated from the computer driven model
of enzymatic-digestion. In addition, a BLAST search was
performed on the LG3 peptide sequence identified and it was
found that no other known protein/peptide shares sequence
homology above 88% coverage.
(DOC)
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